Tag: Biotech and Pharma

Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. 

UK pharmaceutical group forecasts 7-9% revenue growth this year on strong performance from cancer and HIV drugs

Pfizer Inc.’s stock rose 2.7% early Tuesday, after the company blew past earnings estimates for the second quarter, offered an update on a cost-cutting plan and raised its revenue and profit guidance for the year.

Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug.

Abbott Laboratories shares were falling ahead of the opening bell on Monday after a jury found the company had failed to warn that its premature baby formula could increase infants’ risk of developing a potentially deadly bowel illness.

 Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.

Johnson & Johnson stock was slipping Wednesday after the pharmaceutical company beat expectations for its second-quarter earnings.

Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate.

Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw “encouraging” data in an ongoing early-stage study.

The Grifols family and Canadian fund Brookfield have agreed to launch a joint takeover bid for Spanish drugmaker Grifols  with the intent to delist it, the companies said in regulatory filings on Monday.

Eli Lilly & Co. agreed to buy U.S. gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental pipeline.

 UK’s competition regulator said on Monday it has cleared U.S. medical equipment maker Thermo Fisher Scientific’s $3.1 billion deal to buy Swedish biotech firm Olink Holding AB.

Roche Holding said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer after it failed to meet the trial’s primary efficacy goals.

Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were “key methodological limitations” to the study

GSK’s London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.

Novo Nordisk’s hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world’s second-largest economy and the country estimated to hold the highest number of overweight or obese people.

Eurofins Scientific shares plunged on Monday after Muddy Waters Research said in a report it had started shorting the laboratory-services company, alleging founder and Chief Executive Gilles Martin has spent decades “covertly enriching” himself through improper real-estate deals.

Shares of Denmark’s Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced positive results.

Sarepta Therapeutics Inc.’s (SRPT) gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials.

Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for allegedly causing cancer.